Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Fey

Showing results (141-150 of 161) with videos related to

Pageof 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1997
Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK)M Fopp, M F Fey, M Bacchi, et al.
Leukemia & Lymphoma|October 24, 2000
Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemiaT Pabst, U R Peters, M Tinguely, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK)D C Betticher, D Ratschiller, S F Hsu Schmitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK)R Morant, J Bernhard, R Maibach, et al.
International Journal of Cancer|August 30, 2000
Differential expression of p73 splice variants and protein in benign and malignant ovarian tumoursD Zwahlen, M P Tschan, T J Grob, et al.
Oncogene|December 5, 1998
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpressionS Vonlanthen, J Heighway, M P Tschan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphomaD C Betticher, A von Rohr, D Ratschiller, et al.
Cell Death and Differentiation|December 26, 2001
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53T J Grob, U Novak, C Maisse, et al.
Biochemical and Biophysical Research Communications|October 12, 2000
Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemiaM P Tschan, T J Grob, U R Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemiaU Novak, T J Grob, G Baskaynak, et al.
Pageof 17

Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1997
Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK)M Fopp, M F Fey, M Bacchi, et al.
Leukemia & Lymphoma|October 24, 2000
Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemiaT Pabst, U R Peters, M Tinguely, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK)D C Betticher, D Ratschiller, S F Hsu Schmitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK)R Morant, J Bernhard, R Maibach, et al.
International Journal of Cancer|August 30, 2000
Differential expression of p73 splice variants and protein in benign and malignant ovarian tumoursD Zwahlen, M P Tschan, T J Grob, et al.
Oncogene|December 5, 1998
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpressionS Vonlanthen, J Heighway, M P Tschan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphomaD C Betticher, A von Rohr, D Ratschiller, et al.
Cell Death and Differentiation|December 26, 2001
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53T J Grob, U Novak, C Maisse, et al.
Biochemical and Biophysical Research Communications|October 12, 2000
Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemiaM P Tschan, T J Grob, U R Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemiaU Novak, T J Grob, G Baskaynak, et al.
Pageof 17